Clinical Trial Update: Study to Evaluate Safety, Reactogenicity and Immunogenicity of the Pneumococcal Protein PhtD Vaccine in Healthy Adults [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the safety, reactogenicity and immunogenicity of the pneumococcal protein PhtD vaccine in healthy adults has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• PhtD vaccine (PhtD vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pneumococcal Disease | Phase 1 | Status: COMPLETED